Skip to main content
Publications
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030
Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.
Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X, Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008
Morelli X, Foraster M, Aguilera I, Basagana X, Corradi E, Deltell A, Ducret-Stich R, Phuleria H, Ragettli MS, Rivera M, Thomasson A, Kunzli N, Slama R. Short-term associations between traffic-related noise, particle number and traffic flow in three European citie. Atmos Environ. 2015 Feb;103:25-33. doi: 10.1016/j.atmosenv.2014.12.012
Ragettli MS, Ducret-Stich RE, Foraster M, Morelli X, Aguilera I, Basagana X, Corradi E, Ineichen A, Tsai M, Probst-Hensch N, Rivera M, Slama R, Kunzli N, Phuleria HC. Spatio-temporal variation of urban ultrafine particle number concentrations. Atmos Environ. 2014 Oct;96:275-83. doi: 10.1016/j.atmosenv.2014.07.049
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019
Basagana X, Rivera M, Aguilera I, Agis D, Bouso L, Elosua R, Foraster M, de Nazelle A, Nieuwenhuijsen M, Vila J, Kunzli N. Effect of the number of measurement sites on land use regression models in estimating local air pollution. Atmos Environ. 2012 Jul;54:634-42. doi: 10.1016/j.atmosenv.2012.01.064